Literature DB >> 33948734

Cluster Headache: A Review and Update in Treatment.

Himanshu Suri1, Jessica Ailani2.   

Abstract

PURPOSE OF REVIEW: The treatment of cluster headache has evolved to include a handheld neuromodulation device and a monoclonal antibody in addition to more traditional agents. RECENT
FINDINGS: Galcanezumab is an approved treatment for episodic cluster headache. The non-invasive vagal nerve stimulator has been shown to be effective as a treatment for episodic cluster headache. Dedicated pituitary imaging may not be necessary with a normal MRI of the brain. Cluster headache is the most common trigeminal-autonomic cephalalgia, characterized by unilateral, frequent, debilitating attacks associated with ipsilateral autonomic symptoms. Attacks have a circadian and, often, seasonal pattern with periods of remission that can last months to years in episodic patients. Though a rare disease, an increasing number of studies have revealed novel targets for treatment. Treatment in cluster headache should focus on early intervention to reduce frequency of attacks and the length of the cycle, which improves outcomes and disability. Acute therapy is used to treat attacks, while bridging and preventive therapies are combined to reduce cycle length. Case 1: A 43-year-old man presents with the chief complaint of severe headaches. Upon general examination, he seems uncomfortable, agitated, and exhausted. He states that he hasn't "slept in over a week because of debilitating headaches." His headaches start around the same time every night: when he lays down to go to sleep. The pain is described as sharp, like a "hot poker" to his left eye. His partner has noticed that his eye droops and turns red when the pain starts. The attacks come on abruptly and prevent him from sleeping. The severe pain lasts 30 to 45 min, but he has mild-to-moderate pain that lingers for the rest of the night. He has seen his primary care physician, an allergist, and an ear, nose, and throat (ENT) specialist before coming to see a neurologist. Similar headaches occurred last year during the month of October as well. On further questioning, he reports that these headache attacks have been occurring almost yearly for the past 7 years. Each year, these headaches come on as the weather is changing and occur on a nightly basis for about 3 to 4 weeks.

Entities:  

Keywords:  Acute therapies; Bridging therapies; Cluster headaches; Preventive therapies; Treatment

Mesh:

Year:  2021        PMID: 33948734     DOI: 10.1007/s11910-021-01114-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  45 in total

1.  Testosterone replacement therapy for treatment refractory cluster headache.

Authors:  Mark J Stillman
Journal:  Headache       Date:  2006-06       Impact factor: 5.887

Review 2.  Diagnosis, pathophysiology, and management of cluster headache.

Authors:  Jan Hoffmann; Arne May
Journal:  Lancet Neurol       Date:  2017-11-23       Impact factor: 44.182

Review 3.  Pathophysiology of cluster headache: a trigeminal autonomic cephalgia.

Authors:  Peter J Goadsby
Journal:  Lancet Neurol       Date:  2002-08       Impact factor: 44.182

4.  Unilateral cranial autonomic symptoms in migraine.

Authors:  P Barbanti; G Fabbrini; M Pesare; N Vanacore; R Cerbo
Journal:  Cephalalgia       Date:  2002-05       Impact factor: 6.292

5.  Low plasma testosterone levels in cluster headache.

Authors:  A Romiti; P Martelletti; M F Gallo; M Giacovazzo
Journal:  Cephalalgia       Date:  1983-03       Impact factor: 6.292

Review 6.  Cluster headache and obstructive sleep apnea: are they related disorders?

Authors:  Steven B Graff-Radford; Antonia Teruel
Journal:  Curr Pain Headache Rep       Date:  2009-04

Review 7.  The incidence and prevalence of cluster headache: a meta-analysis of population-based studies.

Authors:  M Fischera; M Marziniak; I Gralow; S Evers
Journal:  Cephalalgia       Date:  2008-04-16       Impact factor: 6.292

Review 8.  Cluster headache.

Authors:  Jacqueline Weaver-Agostoni
Journal:  Am Fam Physician       Date:  2013-07-15       Impact factor: 3.292

9.  Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies.

Authors:  P J Goadsby; L Edvinsson
Journal:  Brain       Date:  1994-06       Impact factor: 13.501

10.  The role of neuroimaging in the diagnosis of headache disorders.

Authors:  Dagny Holle; Mark Obermann
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.